Guilherme Cantuaria, MD
Gynecologic Oncology · Atlanta, GANPI 1871530634
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,173 of the $12,975 with a category attached, or 78.4%. GSK accounts for 63.0% of it on its own, with 24 other manufacturers making up the rest.
Across 118 payments — averaging $109.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- AstraZeneca$3K
- Merck$475
- Pfizer$314
- Caris MPI, Inc.$182
- Eisai Inc.$163
- plus $919 from 19 others
Across 41 payments — averaging $12,097 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$347K
- GSK$126K
- Pfizer$13K
- AstraZeneca$10K
What the payments were for
- Consulting fees$10,17378%
- Food & beverage$2,69921%
- Education$1031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $8,168 |
| AstraZeneca | 17 | $2,754 |
| Merck | 17 | $475 |
| Pfizer | 14 | $314 |
| Caris MPI, Inc. | 2 | $182 |
| Eisai Inc. | 7 | $163 |
| Amgen | 3 | $138 |
| Tesaro, Inc. | 5 | $125 |
| Clovis Oncology, Inc. | 7 | $111 |
| Myriad Genetic Laboratories, Inc. | 5 | $106 |
| Novartis | 2 | $54 |
| BD | 1 | $50 |
| Seagen Inc. | 2 | $38 |
| Coherus Oncology, Inc. | 2 | $35 |
| AbbVie | 2 | $35 |
| Therapeuticsmd, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $30 |
| Covidien LP | 2 | $28 |
| Immunogen, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $21 |
| Davol Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Dysis Medical, Inc. | 1 | $13 |
| Hydrofera LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEMPERLI$2,900
- LYNPARZA$2,398
- ZEJULA$2,275
- MI CANCER SEEK$163
- KEYTRUDA$111
How this compares
$12,975 in reported general payments places this provider in the 80th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 14 | $125 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $105 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Atlanta
- Benedict BenignoAtlanta$273K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Cyril SpannAtlanta$12K
- Kevin AultAtlanta$10K
- Leda GattocAtlanta$7K
- Jennifer ScaliciAtlanta$6K
- Oi Wah YapAtlanta$3K
- Namita KhannaAtlanta$3K
- Joseph BoveriAtlanta$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.